Governor's COVID-19 Vaccine Advisory Group

Thursday, December 17, 2020







Before We Begin

- *Please remain muted
- *Raise Hand
- *Feel free to use Comments section
- *Parking Lot

Welcome

Commissioner Deidre Gifford, MD Reginald Eadie, MD







DPH Agenda Connecticut Department

Agenda

1.	Welcome and Roll Call	Commissioner Gifford	
		Dr. Eadie	
2.	Vaccine Program Update	Benjamin Bechtolsheim	
	a. Updates from Week One	Kathy Kudish	
	b. Roll-out Plans for Upcoming Weeks		
3.	Subcommittee Reports	Sen. Somers	
	 a. Key Decisions and Recommendations 	Jason Schwartz	
	b. Next Steps	Nichelle Mullins	
	c. Questions and Discussion with the Group		
4.	Open Discussion	Advisory Group members	
5.	New Directions to Subcommittees	Advisory Group members	
6.	Next Advisory Group Meeting	Advisory Group members	
	a. Determine Meeting Cadence for Advisory Group	Subcommittee Co-Chairs	
	b. Identify Next Subcommittee Meetings		
7.	Wrap-Up	Mike Mozzer	
		Benjamin Bechtolsheim	
8.	Adjourn		

Vaccine Program Update

Benjamin Bechtolsheim Kathy Kudish







Current timeline



	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
	Nov 29	30	Dec 1	2	3	4	5
	6	7	8	9	10 FDA VRBPAC	EUA issued	ACIP recommend
Week 1 Pfizer only	13 First shipments	14 Arrival of first shipments	15 in CT Allocation Committee	16	17 (today) FDA VRBPAC Governor's Vaccine Advisory Group	Window for EUA & ACFIRST LTCF clinics Science Committee	19 CIP Guidance
Week 2 Pfizer, introduction of Moderna	20	LTCF vaccinations Allocation Committee	22	23	24	25	26
Week 3 Pfizer & Moderna	27	28	29	30	31	1	2



Current stats (as of end of day, Wed 12/16)

Doses administered

	Doses administered yesterday	Doses administered in last 3 days	Total cumulative doses
	(Wednesday)	(Mon, Tue, Wed)	Since program start
Hospitals	1,636	1,982	1,982
LTCFs	0	0	0
Total	1,636	1,982	1,982

Shipments received & forecast

	Doses received this week	Doses expected next week	Total cumulative received	
	(Dec 14-20)	(Dec 21-28)	(Dec 14-20)	
Pfizer	31,200	22,425	31,200	
Moderna	0	63,300	0	
Total	31,200	85,725	31,200	

The Advisory Committee on Immunization Practices (ACIP) recommends that when a COVID-19 vaccine is authorized by the FDA and recommended by ACIP, vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a) should be offered to both

- 1) Healthcare personnel (HCP): all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials.
- 2) Residents of long-term care facilities (LTCF): Adults who reside in facilities that provide a range of services, including medical and personal care, to persons who are unable to live independently.

The State of Connecticut has further clarified that the following individuals are included in Phase 1a:

3) First responders at risk of exposure to COVID-19 (e.g., EMTs, Fire, Police who respond to medical 911 calls)

NO FINAL DECISIONS ABOUT PHASE 1B HAVE YET BEEN MADE
LIKELY TO INCLUDE "ESSENTIAL WORKFORCE" AS PART OF PHASE 1B

Detail about Phase 1a ACIP recommendations can be found <u>here</u> and <u>here</u>



Detail on vaccine access for Phase 1a populations

For LTCF residents & staff:

First clinics likely to begin on 12/21 at skilled nursing facilities – assisted living and other long-term care facilities will follow shortly thereafter

Clinics to be conducted on site at LTCFs, administered by pharmacy partners (CVS & Walgreens) through the Pharmacy Partnership for Long-Term Care

First facilities will include skilled nursing facilities, after which clinics will rapidly proceed in assisted living facilities, continuing care retirement communities, intermediate care facilities for adults with developmental disabilities, veteran's homes, and HUD 202 program housing

Residents and staff will receive more information from their facility leadership as well as directly from CVS / Walgreens about how to prepare

Details on program

For healthcare personnel & first responders

First clinics beginning this week

First-week clinics will be on-site at acute-care hospitals

In subsequent weeks, vaccinations will be available at broad range of other settings, including local health departments, FQHCs, other clinics. These providers are currently being enrolled, and timing of first non-hospital clinics is partially dependent on supply availability

Detail on next page about how access will be ensured

Communications Subcommittee

Sen. Heather Somers and Dr. Joseph Quaranta







Subcommittee Mandate

- *Communicate the who, when, where, why and how relative to COVID-19 Vaccination
- *Will need to engage members of the community who
 - *Are not able to receive messages through "traditional" channels
 - *Have vaccine hesitancy
- *Questions to answer:
 - *Who are stakeholders?
 - *How messages should be disseminated (e.g., PSA, video, "town halls")
 - *Consistency of message



Key Updates and Recommendations

- *Committee has held three meetings
- *Engaged Governor/DPH Comms and Vaccination Staff
- *Key Recommendations
 - *Robust and proactive communications about COVID-19 vaccines; Set expectations for their availability
 - *Use multiple communication channels to reach diverse audiences
 - *Utilize the Science Subcommittee as a subject matter expert panel to provide testimonials about the importance and safety of the vaccine
 - *Engage the Communications Subcommittee as a Stakeholder Partners Panel to communicate messaging to their respective stakeholders.



Plan Moving Forward

- *Shift focus of subcommittee from developing recommendations to:
 - *Serving as ambassadors to amplify Governor's/DPH's messaging
 - *Receive regular messages/updates from DPH
 - *Push messages to stakeholder groups
 - *Collaborate with Science Committee Subject Matter Experts on outreach
 - *Serve as a listening body to report rumors/misinformation to Comms team
 - *Provide ongoing recommendations on Comms strategy

Science Subcommittee

Jason Schwartz and David Banach, MD







Subcommittee Mandate

Confirm the integrity of the Food and Drug Administration (FDA) approval / emergency use authorization (EUA) process

- *Evaluate EUA process and outcome and confirm that the State of Connecticut should begin vaccination
- *Separate subcommittee review and recommendation for each vaccine

Deliverables:

- *Letter to advisory group co-chairs regarding assessment of EUA and recommendation whether to begin vaccination pending release of ACIP recommendations. (Requested timeline: within 18 hours of issuance of an EUA.)
- *Meeting minutes submitted to advisory group; includes subcommittee discussions and additional comments provided by members



Key Updates and Recommendations

- *Last week: review of Pfizer-BioNTech vaccine
 - *12/8: Documents regarding vaccine and clinical trial data released by FDA
 - *12/10: Meeting of FDA Vaccines and Related Biological Products Advisory Committee; VRBPAC vote in support of EUA
 - *12/11: Meeting of Science Subcommittee; EUA issued by FDA
 - * 12/12: Science Subcommittee recommendation to begin vaccination in Connecticut at the earliest opportunity using this vaccine and consistent with ACIP recommendations
 - * 12/13: Statement from Gov. Lamont that recommendation had been accepted; ACIP recommendations approved
 - *12/14: First vaccine doses arrived in Connecticut; vaccination began

^{*}Recent subcommittee meetings: 11/30 and 12/11; between meetings, sharing of materials and further discussion via email



Plan Moving Forward

- *This week: review of Moderna vaccine
 - * 12/15: Documents regarding vaccine and clinical trial data released by FDA
 - * 12/17: Meeting of FDA Vaccines and Related Biological Products Advisory Committee
 - * 12/18: Meeting of Science Subcommittee
 - * Expected in coming days:
 - * FDA decision on EUA
 - * Subcommittee recommendation finalized and submitted to advisory group co-chairs
 - * ACIP recommendations, vaccine doses delivered, vaccination begins
- *Monday, 12/28: next regularly scheduled meeting

Allocation Subcommittee

Nichelle Mullins and Zita Lazzarini







Subcommittee Mandate

Review ACIP guidelines and provide recommendation for changes to sequence or offering clarification for how ACIP guidelines should be applied in the State of Connecticut.



Key Updates and Recommendations

- *December 2, 2020 meeting:
 - * Provided feedback and recommendations on initial Phase 1A allocation
- *December 15, 2020 meeting:
 - *Clarified populations included in Phase 1A
 - *Communication/clarification to public regarding availability of vaccine as well as populations recommended for each distribution phase
 - * Reviewed ACIP's initial Phase 1B recommendations



Plan Moving Forward

- *The Subcommittee will continue to meet regularly as needed, and within 48 hours of the ACIP meetings, to ensure that they are keeping up with the issues surrounding allocation.
- *ACIP is scheduled to vote on Phase 1B and Phase 1C recommendations on December 20, 2020.
 - *Allocation subcommittee meeting December 21, 2020 (12:00-2:00)-tentative
 - *Written recommendations for Phase 1B allocation to Commissioner Gifford and Dr. Eadie- December 22, 2020

Open Discussion







Administrative Updates

- *Determine meeting cadence moving forward
- * https://portal.ct.gov/DPH/Communications/Disease-Preparedness/COVID-19-Vaccine-Advisory-Group
 - *Agendas, meeting recordings, meeting summaries
- *Parking Lot

Questions?





Thank you for your participation



